Evidence map›Paper›PMID 34138728›Full record

ArticleScience advances2021

Scaffold-mediated CRISPR-Cas9 delivery system for acute myeloid leukemia therapy.

Tzu-Chieh Ho, Hye Sung Kim, Yumei Chen, Yamin Li, Mark W LaMere, Caroline Chen, Hui Wang, Jing Gong, Cal D Palumbo, John M Ashton and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
6.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 115 citations in OpenAlex.

  1. Article
  2. Review
  3. Endogenous Engineering Reprograms Extracellular Vesicles for Enhanced Therapeutic Function.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  4. Review
  5. Review
  6. Nature Inspired Delivery Vehicles for CRISPR-Based Genome Editing.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Pioneering biomimetic biomaterial for leukemia therapy enhancement: a review.Frontiers in bioengineering and biotechnology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Tzu-Chieh HoDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.ORCID 0000-0002-2913-9319
Hye Sung KimDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.ORCID 0000-0002-2182-301X
Yumei ChenDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Yamin LiDepartment of Biomedical Engineering, Tufts University, Boston, MA, USA.ORCID 0000-0002-5535-1807
Mark W LaMereWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.ORCID 0000-0002-1701-7955
Caroline ChenDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Hui WangHumanized Mouse Core Facility, Columbia Center for Translational Immunology, Columbia University, New York, NY, USA.ORCID 0000-0002-6638-0283
Jing GongDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.ORCID 0000-0003-1320-7345
Cal D PalumboWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
John M AshtonWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.ORCID 0000-0001-9875-5994
Hae-Won KimInstitute of Tissue Regeneration Engineering, Dankook University, Cheonan, Republic of Korea.ORCID 0000-0001-6400-6100
Qiaobing XuDepartment of Biomedical Engineering, Tufts University, Boston, MA, USA.ORCID 0000-0001-7323-7795
Michael W BeckerWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA. michael_becker@urmc.rochester.edu kam.leong@columbia.edu.ORCID 0000-0001-9890-8815
Kam W LeongDepartment of Biomedical Engineering, Columbia University, New York, NY, USA. michael_becker@urmc.rochester.edu kam.leong@columbia.edu.ORCID 0000-0002-8133-4955
Columbia University · USUniversity of Rochester Medical Center · USTufts University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leukemia stem cells (LSCs) sustain the disease and contribute to relapse in acute myeloid leukemia (AML). Therapies that ablate LSCs may increase the chance of eliminating this cancer in patients. To this end, we used a bioreducible lipidoid-encapsulated Cas9/single guide RNA (sgRNA) ribonucleoprotein [lipidoid nanoparticle (LNP)-Cas9 RNP] to target the critical gene interleukin-1 receptor accessory protein (

Indexed as

CRISPR-Cas SystemsLeukemia, Myeloid, AcuteGene EditingHumansRibonucleoproteinsRNA, Guide, CRISPR-Cas SystemsTumor MicroenvironmentRibonucleoproteinsRNA, Guide, CRISPR-Cas Systems

Identifiers

PMID34138728
PMCPMC8133753
OpenAlexW3162661003

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.